For years, the development of drugs for respiratory diseases, mainly asthma and chronic obstructive pulmonary disease (COPD), have relied on the administration of a new drug, mostly by inhalation and assessment by physiologic tests and questionnaires. More and more these new drugs are administered in fixed combinations.
This white paper outlines the latest respiratory R&D trends encompassing outcomes and clinical trial study designs.
100 Nanglinchee Road,
Chongnonsee, Yannawa, 10120,